Prognostic Factors Associated With Decreased Survival in Patients With Acinic Cell Carcinoma | Gastroenterology | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.186.91. Please contact the publisher to request reinstatement.
1.
McHugh  JB, Visscher  DW, Barnes  EL.  Update on selected salivary gland neoplasms.  Arch Pathol Lab Med. 2009;133(11):1763-1774.PubMedGoogle Scholar
2.
Ellis  GL,Auclair  PL.  Tumors of the Salivary Glands: Atlas of Tumor Pathology. Washington, DC: Armed Forces Institute of Pathology; 2008:204-225.
3.
Howlader NNA, Krapcho M, Neyman N, et al. SEER cancer statistics review, 1975-2009 (vintage 2009 populations). 2011. seer.cancer.gov/csr/1975_2009_pops09/. Accessed April 15, 2012.
4.
Hanna  EYNSJ. Malignant tumors of the salivary gland. In: Myers  ESJ, Myers  J, Hanna  E, eds.  Cancer of the Head and Neck.4th ed. Philadelphia, PA: WB Sanders; 2003:475-510.
5.
Hoffman  HT, Karnell  LH, Robinson  RA, Pinkston  JA, Menck  HR.  National Cancer Data Base report on cancer of the head and neck.  Head Neck. 1999;21(4):297-309.PubMedGoogle ScholarCrossref
6.
Perzin  KH, LiVolsi  VA.  Acinic cell carcinomas arising in salivary glands.  Cancer. 1979;44(4):1434-1457.PubMedGoogle ScholarCrossref
7.
Batsakis  JG, Luna  MA, el-Naggar  AK.  Histopathologic grading of salivary gland neoplasms, II.  Ann Otol Rhinol Laryngol. 1990;99(11):929-933.PubMedGoogle Scholar
8.
Seifert  G, Sobin  LH.  The World Health Organization’s Histological Classification of Salivary Gland Tumors.  Cancer. 1992;70(2):379-385.PubMedGoogle ScholarCrossref
9.
Spiro  RH, Huvos  AG, Strong  EW.  Adenocarcinoma of salivary origin.  Am J Surg. 1982;144(4):423-431.PubMedGoogle ScholarCrossref
10.
Schwarz  S, Zenk  J, Müller  M,  et al.  The many faces of acinic cell carcinomas of the salivary glands.  Histopathology. 2012;61(3):395-408.PubMedGoogle ScholarCrossref
11.
Cox  DR, Oakes  D.  Analysis of Survival Data. London, England: Chapman and Hall; 1984.
12.
Klein  JP, Moeschberger  ML.  Survival Analysis: Techniques for Censored and Truncated Data.2nd ed. Dordrecht, the Netherlands: Springer Science+Business Media; 2003.
13.
Tu  G, Hu  Y, Jiang  P, Qin  D.  The superiority of combined therapy (surgery and postoperative irradiation) in parotid cancer.  Arch Otolaryngol. 1982;108(11):710-713.PubMedGoogle ScholarCrossref
14.
Guillamondegui  OM.  Salivary gland cancers, surgery, and irradiation therapy.  Arch Otolaryngol. 1982;108(11):709.PubMedGoogle ScholarCrossref
Original Investigation
November 2013

Prognostic Factors Associated With Decreased Survival in Patients With Acinic Cell Carcinoma

Author Affiliations
  • 1Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston
  • 2School of Medicine, Temple University Medical School, Philadelphia, Pennsylvania
  • 3Department of Statistics, Rice University, Houston, Texas
  • 4Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston
  • 5Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston
  • 6Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston
JAMA Otolaryngol Head Neck Surg. 2013;139(11):1195-1202. doi:10.1001/jamaoto.2013.4728
Abstract

Importance  Acinic cell carcinoma is a rare salivary neoplasm that is generally associated with a good prognosis, although a subset of patients develops local and distant recurrences. Given the rarity of the disease, factors to identify patients at risk for recurrences or decreased survival are not clearly defined.

Objectives  To identify clinicopathologic factors associated with adverse survival in patients with acinic cell carcinoma and to assess the effect of local, regional, and distant recurrences on survival.

Design, Setting, and Participants  Retrospective medical record review in a tertiary care cancer center of 155 patients treated for acinic cell carcinoma from January 1990 through Febraury 2013.

Main Outcomes and Measures  Primary outcomes evaluated were overall and disease-free survival. The end points assessed were age at diagnosis, sex, size of primary tumor, presence of positive surgical margins, postoperative radiation therapy, and development of local, regional, or distant recurrences.

Results  The median survival was 28.5 years, with 13 patients (8.4%) dying of their disease. Women (n = 104) were affected twice as often as men (n = 51) but had an improved survival (P < .001). Patients diagnosed as having acinic cell carcinoma before or at the age of 45 years had an improved survival (P = .02) compared with their elder counterparts, a finding that was independent of sex. Neoplasms larger than 3 cm at presentation were associated with a decreased overall survival compared with smaller lesions (P = .02). The development of distant metastases was most associated with death from the disease (odds ratio, 49.90; 95% CI, 6.49-2246.30; P <.001) compared with local and regional recurrences.

Conclusions and Relevance  Although patients with acinic cell carcinoma generally have a favorable prognosis, we have identified several factors associated with decreased survival, including male sex, age older than 45 years, neoplasms larger than 3 cm, and the development of a distant recurrence. These results suggest that maximizing local and regional control for this disease can offer substantial benefit when no distant disease is detectable.

×